- Home
- RVPH vs FGEN Comparison
RVPH vs FGEN Comparison
Compare RVPH & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- FGEN
- Stock Information
- Founded
- RVPH 2006
- FGEN 1993
- Country
- RVPH United States
- FGEN United States
- Employees
- RVPH N/A
- FGEN N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- RVPH Health Care
- FGEN Health Care
- Exchange
- RVPH Nasdaq
- FGEN Nasdaq
- Market Cap
- RVPH 33.4M
- FGEN 34.0M
- IPO Year
- RVPH N/A
- FGEN 2014
- Fundamental
- Price
- RVPH $1.22
- FGEN $0.35
- Analyst Decision
- RVPH Strong Buy
- FGEN
- Analyst Count
- RVPH 4
- FGEN 0
- Target Price
- RVPH $15.33
- FGEN N/A
- AVG Volume (30 Days)
- RVPH 661.2K
- FGEN 1.6M
- Earning Date
- RVPH 11-14-2024
- FGEN 11-12-2024
- Dividend Yield
- RVPH N/A
- FGEN N/A
- EPS Growth
- RVPH N/A
- FGEN N/A
- EPS
- RVPH N/A
- FGEN N/A
- Revenue
- RVPH N/A
- FGEN $180,015,000.00
- Revenue This Year
- RVPH N/A
- FGEN $20.42
- Revenue Next Year
- RVPH N/A
- FGEN N/A
- P/E Ratio
- RVPH N/A
- FGEN N/A
- Revenue Growth
- RVPH N/A
- FGEN 16.15
- 52 Week Low
- RVPH $0.60
- FGEN $0.18
- 52 Week High
- RVPH $5.67
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- RVPH 52.82
- FGEN 51.18
- Support Level
- RVPH $1.09
- FGEN $0.33
- Resistance Level
- RVPH $1.37
- FGEN $0.43
- Average True Range (ATR)
- RVPH 0.15
- FGEN 0.05
- MACD
- RVPH 0.03
- FGEN 0.01
- Stochastic Oscillator
- RVPH 58.77
- FGEN 69.39
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.